Skip to main
LUCD
LUCD logo

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics Inc. is projected to have significant upside potential based on its valuation, which balances high risks with substantial opportunities in the medical diagnostics market. The company's advancements with Medicare suggest the potential for positive coverage announcements, which could enhance its market position and drive revenue growth. Additionally, EsoGuard’s first mover advantage and superior testing capabilities position Lucid as an appealing acquisition target, further supporting a positive outlook for the company’s stock.

Bears say

Lucid Diagnostics Inc reported a pro forma net loss of $9.9 million, resulting in an earnings per share (EPS) of $(0.10), slightly worse than internal estimates of $(0.09) and consensus expectations of $(0.12). Furthermore, the volume of EsoGuard tests processed decreased significantly to 2,756 in Q2, down from prior quarterly figures, indicating a troubling decline in demand for the company's primary product. The company also faces numerous risks, including liquidity concerns, product efficacy, regulatory approval, reimbursement challenges, and heightened competition, all contributing to a negative outlook for its stock.

Lucid Diagnostics (LUCD) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.